{"gene":"LRRK2","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2007,"finding":"LRRK2 possesses both kinase and GTPase activity. Purified brain LRRK2 binds and hydrolyzes GTP. PD mutations R1441C/G in the GTPase (ROC) domain reduce GTP hydrolysis activity. GTPase activity of LRRK2 can function independently of kinase activity, whereas kinase activity requires the presence of the GTPase domain.","method":"In vitro GTP binding and hydrolysis assays using purified LRRK2 from transgenic mouse brain and transfected cell cultures; domain deletion constructs","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzymatic assay with purified protein, domain-deletion and mutant constructs, replicated across tissue and cell systems","pmids":["17623048"],"is_preprint":false},{"year":2007,"finding":"C. elegans LRK-1 (LRRK2 ortholog) localizes to the Golgi apparatus and is required for polarized sorting of synaptic vesicle (SV) proteins to axons. In lrk-1 deletion mutants, SV proteins mislocalize to dendrites. This mislocalization depends on the AP-1 µ1 adaptor UNC-101 (dendritic transport) but not on UNC-104 kinesin (axonal transport), placing LRK-1 upstream of the dendritic sorting machinery at the Golgi.","method":"C. elegans genetics; lrk-1 deletion mutants; in vivo imaging of fluorescently tagged SV proteins; epistasis with unc-101 and unc-104 mutants; immunolocalization of LRK-1 to Golgi","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic loss-of-function with defined cellular phenotype, epistasis analysis, and direct localization in a validated ortholog model","pmids":["17346966"],"is_preprint":false},{"year":2007,"finding":"Loss of Drosophila LRRK (sole ortholog of human LRRK2) causes degeneration of dopaminergic neurons (reduced tyrosine hydroxylase staining, shrunken morphology) and severely impaired locomotor activity, establishing an in vivo requirement for LRRK2 in dopaminergic neuron integrity.","method":"Drosophila loss-of-function mutants (LRRK deletion); tyrosine hydroxylase immunostaining; locomotor behavioral assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with specific neuronal phenotype in an ortholog model, two orthogonal readouts (immunostaining + behavior), single lab","pmids":["17498648"],"is_preprint":false},{"year":2014,"finding":"LRRK2 negatively regulates PKA activity in striatal projection neurons (SPNs) by interacting with PKA regulatory subunit IIβ (PKARIIβ). Loss of LRRK2 promotes synaptic translocation of PKA and increases PKA-mediated phosphorylation of cofilin and GluR1, causing abnormal synaptogenesis. The PD-linked R1441C mutation impairs LRRK2–PKARIIβ interaction, leading to excessive PKA activity.","method":"Co-immunoprecipitation; LRRK2 knockout mice; PKA activity assays; phosphorylation assays for cofilin and GluR1; synaptic fractionation; R1441C knock-in mice","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP identifying binding partner, KO and knock-in mice with defined cellular and biochemical phenotypes, multiple orthogonal methods","pmids":["24464040"],"is_preprint":false},{"year":2015,"finding":"LRRK2 kinase inhibition leads to dephosphorylation of Ser935 followed by ubiquitination (via K48 and K63 linkages) and degradation of LRRK2. PD mutations (R1441G, Y1699C, I2020T) and disruption of 14-3-3 binding (via difopein) also cause LRRK2 dephosphorylation and hyper-ubiquitination. Phosphatase activity is directly required for inhibitor/mutant-induced ubiquitination (calyculin A treatment prevents both dephosphorylation and increased ubiquitination).","method":"LRRK2 kinase inhibitor treatment (GNE1023); phosphorylation and stability assays in cells and mouse dosing studies; ubiquitination assays (K48/K63 linkage); PD mutant expression; difopein expression; phosphatase inhibitor calyculin A","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (pharmacological inhibition, genetic mutants, phosphatase inhibitor rescue) in cells and in vivo, single lab","pmids":["25939886"],"is_preprint":false},{"year":2015,"finding":"LRRK2 autophosphorylates its own ROC (GTPase) domain, and this phosphorylation enhances GTP hydrolysis rate (~2-fold). Phosphorylation also promotes ROC dimer formation and induces conformational changes at the p-loop. The ameba LRRK2 ortholog ROCO4 can phosphorylate human LRRK2 ROC on the same residues as human LRRK2 kinase.","method":"In vitro kinase assay with purified ROC domain; GTP hydrolysis kinetics (kcat measurement); GDP/GTP dissociation kinetics; size-exclusion chromatography for dimerization; structural modeling; phosphoproteomics alignment","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro enzymatic assay with kinetic measurements, structural modeling, cross-species validation with ROCO4, multiple readouts","pmids":["26396237"],"is_preprint":false},{"year":2017,"finding":"14-3-3 proteins bind LRRK2 at multiple phosphorylated serine residues in a multivalent interaction. Crystal structures of 14-3-3 with LRRK2 phosphopeptides characterize this structural interface. PD-relevant mutations impair 14-3-3 binding, which is linked to enhanced LRRK2 kinase activity, LRRK2 ubiquitination, inclusion body accumulation, and reduced neurite length.","method":"Biochemical binding assays; X-ray crystal structures of 14-3-3 with LRRK2 phosphopeptides","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus biochemical assays characterizing multivalent interaction, single lab but structural validation","pmids":["28202711"],"is_preprint":false},{"year":2018,"finding":"Wild-type LRRK2 kinase activity is selectively enhanced in substantia nigra dopamine neurons in idiopathic PD (iPD) patients and rat models through an oxidative mechanism, resulting in phosphorylation of the LRRK2 substrate Rab10 and downstream abnormalities in mitochondrial protein import and lysosomal function.","method":"Proximity ligation assays (PLA) for pSer1292-LRRK2 and LRRK2/14-3-3 dissociation; postmortem human iPD brain tissue; rat PD models; Rab10 phosphorylation assays; mitochondrial import and lysosomal function assays","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — novel PLA methodology applied to human tissue and two independent animal models, multiple downstream functional readouts, single lab","pmids":["30045977"],"is_preprint":false},{"year":2018,"finding":"LRRK2 modulates α-synuclein propagation in a kinase activity-dependent manner via phosphorylation of RAB35. The PD-linked G2019S mutation (increased kinase activity) enhances α-synuclein propagation efficiency. Constitutive RAB35 activation rescues the reduced α-synuclein propagation phenotype in lrk-1 C. elegans mutants (epistasis). LRRK2 kinase inhibition in mice reduces α-synuclein aggregation and enhances lysosomal degradation of α-synuclein.","method":"Cell culture, C. elegans, and rodent models; kinase inhibitor treatment; RAB35 phosphorylation assays; lrk-1 mutant epistasis with constitutively active RAB35; in vivo mouse synucleinopathy model with LRRK2 inhibitor","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistasis in C. elegans, multiple model systems (cell/worm/rodent), pharmacological and genetic perturbations converging on the same pathway","pmids":["30150626"],"is_preprint":false},{"year":2020,"finding":"LRRK2 is recruited to lysosomes after lysosomal membrane damage (LLOMe treatment) and phosphorylates RAB35 and RAB10, which recruits the motor adaptor protein JIP4 to the lysosomal membrane in a kinase-dependent manner. JIP4 then promotes the formation of LAMP1-negative membranous tubules that release vesicular content from lysosomes — a process named LYTL (LYsosomal Tubulation/sorting driven by LRRK2).","method":"Unbiased proteomic screen for LRRK2 partners at lysosomal membrane; Co-IP; super-resolution live-cell imaging; FIB-SEM; kinase inhibitor treatments; RAB phosphorylation assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — proteomic screen followed by Co-IP, multiple imaging modalities (super-resolution + FIB-SEM), kinase-dependence established, single lab with multiple orthogonal methods","pmids":["33177079"],"is_preprint":false},{"year":2020,"finding":"LRRK2 phosphorylates cytoplasmic PI(3,4,5)P3-positive GTP-Rab10 before EEA1/Rab5 recruitment to macropinosomes, and LRRK2-phosphorylated Rab10 blocks EHBP1L1-mediated recycling tubules from macropinosomes. This stalls fast vesicle recycling to promote PI3K-Akt immunological responses (CCR5-loaded signaling endosomes, Akt activation, chemotaxis) in macrophages, dendritic cells, and microglia.","method":"Mouse and human primary macrophage/DC/microglia cultures; LRRK2 kinase inhibitor treatment; Rab10 knockdown; EHBP1L1 overexpression; endocytosis assays (macropinocytosis, phagocytosis, clathrin-mediated); live-cell imaging; Akt and chemotaxis functional assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple primary cell types, genetic and pharmacological perturbations, multiple orthogonal functional readouts, mechanistic pathway placement","pmids":["32853409"],"is_preprint":false},{"year":2020,"finding":"Endogenous Rab29 knockout does not influence basal LRRK2 activity (measured by Rab10 and Rab12 phosphorylation) in wild-type, LRRK2[R1441C], or VPS35[D620N] knock-in mouse tissues or primary cells. Stimulation of Rab10/Rab12 phosphorylation by endolysosomal stressors (nigericin, monensin, chloroquine, LLOMe) is suppressed by LRRK2 inhibitors but not blocked by Rab29 deficiency.","method":"Rab29 knockout mice; LRRK2/VPS35 knock-in mice; phospho-Rab10 and phospho-Rab12 quantification in brain extracts and primary cells; LRRK2 inhibitor treatment; endolysosomal stress agents","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO in multiple knock-in mouse models, multiple LRRK2 substrates measured, pharmacological controls, negative result is informative and well-controlled","pmids":["33135724"],"is_preprint":false},{"year":2021,"finding":"LRRK2-phosphorylated Rab10 recruits both RILPL2 and Myosin Va to the peri-centriolar region via high-affinity binding to the Myosin Va globular tail domain. In the presence of pathogenic LRRK2, phosphoRab10 retains Myosin Va at pericentriolar membranes (demonstrated by FLIP microscopy) and RILPL2/MyoVa relocalization to the mother centriole blocks ciliogenesis.","method":"Co-immunoprecipitation; fluorescence loss in photobleaching (FLIP) microscopy; overexpression of pathogenic LRRK2; RILPL2 overexpression; ciliogenesis assay in RPE cells; binding domain mapping","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays, FLIP microscopy for dynamics, functional ciliogenesis readout, domain-level mechanistic detail","pmids":["33727250"],"is_preprint":false},{"year":2021,"finding":"Hyperactive LRRK2 (G2019S mutation) disrupts processive axonal autophagosome transport in neurons in a kinase-dependent manner by recruiting the motor adaptor SPAG9/JIP4 to autophagosomal membranes. Increased SPAG9/JIP4 induces abnormal kinesin-1 recruitment and activation, producing a tug-of-war between anterograde and retrograde motors. This transport disruption correlates with defective autophagosome maturation.","method":"Live-cell imaging of autophagosome transport in neurons; LRRK2 G2019S expression; kinase inhibitor treatment; SPAG9/JIP4 recruitment assays; motor protein activity assays; maturation assays","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live imaging with defined cellular phenotype and proposed mechanistic model, kinase-dependence established, single lab","pmids":["34110246"],"is_preprint":false},{"year":2021,"finding":"LRRK2 G2019S kinase activity phosphorylates NSF (N-ethylmaleimide sensitive factor) and induces its accumulation in toxic aggregates. NSF aggregates were observed in basal ganglia of G2019S PD patients and in cellular/animal G2019S models. Autophagy induction clears NSF aggregation and rescues motor/cognitive impairment in aged hG2019S BAC mice.","method":"In vitro kinase assay demonstrating LRRK2 phosphorylates NSF; immunohistochemistry in human PD brain tissue; cell and BAC mouse models; autophagy induction rescue experiments; behavioral assays","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay plus human tissue validation plus animal model rescue, multiple methods, single lab","pmids":["33876242"],"is_preprint":false},{"year":2021,"finding":"Type I LRRK2 inhibitors (GSK3357679A, MLi-2) and Type II inhibitors (GZD-824, Rebastinib, Ponatinib) both suppress phosphorylation of Rab10 and Rab12 and promote mitophagy. Type II inhibitors do not induce dephosphorylation of LRRK2 N-terminal biomarker sites (e.g., Ser935), indicating these biomarker sites report on the open vs. closed kinase conformation rather than purely on catalytic activity. The A2016T resistance mutation confers cross-resistance to both Type I and Type II inhibitors.","method":"Pharmacological comparison of Type I and II inhibitors; pRab10/pRab12 phosphorylation assays; pSer935 and related site assays; mitophagy assays; LRRK2[A2016T] resistance mutant","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple inhibitor classes, multiple substrates and phosphosites, resistance mutant validation, mechanistic interpretation of conformational states","pmids":["34515301"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structure of the LRRK2 catalytic half (kinase in closed conformation + GTPase domain) bound to microtubules identifies GTPase domain residues mediating microtubule binding. Mutagenesis of these residues disrupts microtubule binding in vitro and in cells without affecting kinase activity. LRRK1 (closely related) has a similar overall structure but does not interact with microtubules.","method":"Cryo-EM structure of LRRK2 catalytic half bound to microtubules; comparative structure of LRRK1; site-directed mutagenesis of GTPase residues; in vitro microtubule-binding assay; cell-based microtubule co-localization","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure with mutagenesis validation in vitro and in cells, negative control with LRRK1, mechanistic residue identification","pmids":["36510024"],"is_preprint":false},{"year":2022,"finding":"LRRK2 activation at lysosomes and the phosphorylation of Rab10 (but not Rab12) is restricted to perinuclear lysosomes by lysosomal positioning. Anterograde lysosome transport (via ARL8B/SKIP overexpression or JIP4 knockdown) blocks Rab10 recruitment and phosphorylation by LRRK2 and prevents LYTL tubulation. Conversely, perinuclear lysosomal clustering (via RILP overexpression) increases LRRK2-dependent Rab10 phosphorylation. Phosphatase PPM1H knockdown increases pRab10 signal and lysosomal tubulation in the perinuclear region.","method":"Rapamycin-dependent LRRK2 recruitment to lysosomes; ARL8B/SKIP overexpression; JIP4 knockdown; RILP overexpression; pRab10 and pRab12 quantification by immunofluorescence; PPM1H siRNA knockdown; live-cell imaging","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple gain- and loss-of-function perturbations, differential substrate regulation identified, phosphatase component identified, multiple orthogonal methods","pmids":["36256825"],"is_preprint":false},{"year":2022,"finding":"Directing LRRK2 to any membrane of the endolysosomal pathway (Golgi, lysosomes, plasma membrane, recycling/early/late endosomes) via rapamycin-induced oligomerization is sufficient to trigger local phosphorylation of RAB10, RAB12, and recruitment of JIP4, independent of endogenous RAB29.","method":"Rapamycin-dependent organelle-targeting system; pRAB10 and pRAB12 immunofluorescence; JIP4 recruitment assay; RAB29 knockout cells","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic targeting to multiple organelles, negative control with Rab29 KO, multiple substrate readouts, mechanistic conclusion about membrane sufficiency for activation","pmids":["35580815"],"is_preprint":false},{"year":2023,"finding":"Rab12 acts as a novel regulator of LRRK2 activity at lysosomes. Rab12 is recruited to damaged lysosomes and promotes a local, LRRK2-dependent increase in Rab10 phosphorylation at the lysosome. PD-linked variants LRRK2 R1441G and VPS35 D620N increase LRRK2 recruitment to lysosomes and elevate lysosomal pT73-Rab10 levels.","method":"Targeted siRNA screen; imaging and immunopurification of isolated lysosomes; Rab12 recruitment assays; pRab10 quantification at lysosomes; LRRK2 R1441G and VPS35 D620N knock-in models","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA screen identification plus lysosome-specific assays with immunopurification, multiple PD-linked variants tested, mechanistic pathway defined","pmids":["37874617"],"is_preprint":false},{"year":2023,"finding":"LRRK2 promotes MFN2 degradation via LRRK2-MKK4/JNK-dependent phosphorylation of MFN2 at Ser27, followed by ubiquitination-mediated MFN2 degradation. This leads to mitochondrial fragmentation and increased ROS in proximal renal tubular cells. LRRK2 knockout prevents MFN2 loss and mitochondrial damage in acute kidney injury models.","method":"LRRK2 overexpression in human PTCs; MFN2 phosphorylation (pSer27) assays; ubiquitination assays; LRRK2 KO mice in AKI model; mitochondrial morphology analysis; ROS measurement; in vivo LRRK2 inhibitor pretreatment","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined phosphorylation site on substrate, KO rescue in vivo, pharmacological inhibitor validation, single lab","pmids":["37633049"],"is_preprint":false},{"year":2025,"finding":"STING signaling activates LRRK2 kinase activity and recruits it to lysosomes via the CASM (conjugation of ATG8 to single membranes) pathway. Multiple lysosome-perturbing stimuli (beyond STING) converge on CASM to activate LRRK2. LRRK2 lysosomal recruitment and kinase activation are highly dependent on interactions with the GABARAP subfamily of ATG8 proteins, not other ATG8 family members.","method":"STING activation assays; CASM pathway perturbation; lysosomal recruitment assays; LRRK2 kinase activity assays (pRab readout); selective GABARAP vs. LC3 dependency experiments","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple stimuli converging on common pathway, specific ATG8 family member identified, lysosomal recruitment and kinase activation linked, multiple orthogonal perturbations","pmids":["39812709"],"is_preprint":false},{"year":2015,"finding":"LRRK2 binds focal adhesion kinase (FAK) and phosphorylates FAK at its Thr-X-Arg/Lys (TXR/K) motif(s), reducing FAK autophosphorylation at Y397 and attenuating FAK activity. The G2019S-LRRK2 mutation decreases pY397-FAK levels in brain, microglia, and HEK cells, resulting in impaired microglial motility and delayed isolation of injury sites. LRRK2 kinase inhibitor restores pY397 and rescues microglial motility.","method":"Co-immunoprecipitation of LRRK2 and FAK; in vitro kinase assay (pTXR/K phosphorylation); pY397-FAK quantification in G2019S transgenic mice brain and microglia; microglial motility assays; LRRK2 kinase inhibitor rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP identifies interaction, kinase assay identifies phosphorylation site, in vivo and cell models with functional readout, pharmacological rescue","pmids":["26365310"],"is_preprint":false},{"year":2015,"finding":"LRRK2 interacts with Tau and promotes accumulation of non-monomeric and high-molecular weight Tau species independent of LRRK2 kinase activity. LRRK2 increases Tau secretion, possibly through impairment of Tau proteasomal degradation.","method":"Co-immunoprecipitation of LRRK2 and Tau; biochemical fractionation of Tau species (HMW); proteasomal degradation assays; kinase-dead LRRK2 mutant","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP showing interaction, biochemical assays for Tau species and secretion, kinase-dead mutant, single lab with multiple methods","pmids":["26014385"],"is_preprint":false},{"year":2020,"finding":"LRRK2 pathogenic mutations (R1441C, G2019S) reshape glutamatergic synapse structure and function in striatal SPNs: increased levels and altered nanoscale organization of AMPA receptors, decreased frequency of miniature EPSCs, and altered dendritic spine nano-architecture. Effects are pathway-specific (exaggerated in direct pathway dSPNs for R1441C).","method":"Biochemical synaptic preparations; super-resolution imaging; electrophysiology (mEPSC recording); two-photon glutamate uncaging; R1441C and G2019S knock-in mice; pathway-specific SPN identification","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (biochemistry, super-resolution, electrophysiology, two-photon uncaging) in knock-in mice, single lab","pmids":["33006315"],"is_preprint":false}],"current_model":"LRRK2 is a large multidomain protein with both GTPase (ROC-COR) and serine/threonine kinase activities: its kinase phosphorylates a defined subset of Rab GTPases (including Rab8A/B, Rab10, Rab12, Rab29, Rab35) at a conserved switch-II motif, and this activity is enhanced by PD-linked mutations (especially G2019S in the kinase domain); GTP hydrolysis by the ROC domain is impaired by R1441C/G mutations and is itself regulated by LRRK2 autophosphorylation; LRRK2 is recruited to and activated at endolysosomal membranes through multiple converging signals (lysosomal damage, STING-CASM-GABARAP, Rab12), whereupon phospho-Rab10/35 recruit effectors such as JIP4 to drive lysosomal tubulation/sorting (LYTL), regulate macropinocytosis and immune signaling, and block ciliogenesis via Myosin Va/RILPL2 sequestration; in neurons LRRK2 negatively regulates PKA by binding PKARIIβ, affects axonal autophagosome transport via JIP4/kinesin-1 dysregulation, and phosphorylates NSF and FAK as additional substrates; phosphorylation of LRRK2 itself at Ser910/935/955/973 by upstream kinases promotes 14-3-3 binding and protein stability, while dephosphorylation of these sites—as seen with PD mutations or kinase inhibitors—leads to K48/K63 ubiquitination and degradation of LRRK2."},"narrative":{"mechanistic_narrative":"LRRK2 is a large dual-enzyme protein integrating GTPase (ROC-COR) and serine/threonine kinase activities, in which kinase function requires the GTPase domain and PD-linked ROC mutations (R1441C/G) impair GTP hydrolysis [PMID:17623048]; LRRK2 also autophosphorylates its own ROC domain to enhance GTP hydrolysis and promote ROC dimerization, coupling its two catalytic modules [PMID:26396237]. Its principal signaling output is phosphorylation of a defined set of Rab GTPases—Rab10, Rab12, and Rab35—an activity selectively elevated in idiopathic PD substantia nigra dopamine neurons through an oxidative mechanism with downstream mitochondrial and lysosomal consequences [PMID:30045977], and enhanced by the gain-of-function G2019S kinase mutation [PMID:30150626]. LRRK2 is recruited to and activated on endolysosomal membranes: membrane targeting to essentially any endolysosomal compartment is sufficient to trigger local Rab10/Rab12 phosphorylation and JIP4 recruitment [PMID:35580815], with damaged-lysosome recruitment driven by Rab12 [PMID:37874617] and by STING-CASM signaling acting selectively through GABARAP-family ATG8 proteins [PMID:39812709]. Phospho-Rab effectors execute distinct cellular programs: phospho-Rab10/35 recruit the motor adaptor JIP4 to drive LYsosomal Tubulation/sorting (LYTL) [PMID:33177079], and phospho-Rab10 recruits RILPL2/Myosin Va to the pericentriolar region to block ciliogenesis [PMID:33727250]. LRRK2 kinase activity also disrupts processive axonal autophagosome transport via SPAG9/JIP4-driven aberrant kinesin-1 recruitment [PMID:34110246], regulates macropinosome recycling and PI3K-Akt immune responses in myeloid cells through phospho-Rab10 [PMID:32853409], and modulates α-synuclein propagation via Rab35 [PMID:30150626]. Beyond Rab substrates, LRRK2 phosphorylates FAK to attenuate microglial motility [PMID:26365310] and NSF to promote toxic aggregation [PMID:33876242], and negatively regulates PKA signaling in striatal projection neurons by binding PKARIIβ [PMID:24464040]. LRRK2 stability is governed by phosphorylation of N-terminal sites (e.g. Ser910/935) that recruit 14-3-3 through a multivalent interface [PMID:28202711]; dephosphorylation—triggered by PD mutations, kinase inhibitors, or 14-3-3 disruption—leads to K48/K63 ubiquitination and degradation [PMID:25939886]. Structurally, the closed-kinase catalytic half binds microtubules through defined GTPase-domain residues independently of kinase activity [PMID:36510024]. In model organisms LRRK2 orthologs are required for dopaminergic neuron integrity [PMID:17498648] and Golgi-based polarized sorting of synaptic vesicle proteins [PMID:17346966].","teleology":[{"year":2007,"claim":"Established that LRRK2 is a bifunctional enzyme whose kinase activity depends on its GTPase domain and whose GTP hydrolysis is reduced by PD-linked ROC mutations, defining the molecular architecture for all later signaling work.","evidence":"In vitro GTP binding/hydrolysis assays on purified brain and cell-derived LRRK2 with domain-deletion and R1441C/G constructs","pmids":["17623048"],"confidence":"High","gaps":["Did not identify physiological kinase substrates","Mechanism coupling GTPase state to kinase output not resolved"]},{"year":2007,"claim":"Ortholog genetics linked LRRK2 to neuronal membrane trafficking and dopaminergic neuron survival, providing the first in vivo functional context.","evidence":"C. elegans lrk-1 deletion with SV-protein sorting/epistasis and Drosophila LRRK loss-of-function with TH staining and locomotor assays","pmids":["17346966","17498648"],"confidence":"High","gaps":["Molecular substrates underlying sorting/survival defects unknown","Connection between Golgi sorting role and kinase activity not established"]},{"year":2014,"claim":"Identified a kinase-independent role through which LRRK2 restrains PKA signaling at striatal synapses, showing LRRK2 acts via protein-protein interaction as well as catalysis.","evidence":"Reciprocal Co-IP with PKARIIβ, LRRK2 KO and R1441C knock-in mice, PKA activity and cofilin/GluR1 phosphorylation assays","pmids":["24464040"],"confidence":"High","gaps":["How R1441C specifically weakens PKARIIβ binding not structurally defined","Relationship to kinase-substrate pathway unclear"]},{"year":2015,"claim":"Resolved how LRRK2 stability is regulated, linking N-terminal phosphorylation and 14-3-3 binding to ubiquitin-dependent degradation, explaining why PD mutations and inhibitors destabilize LRRK2.","evidence":"Kinase inhibitor (GNE1023) and PD-mutant studies with K48/K63 ubiquitination assays and calyculin A phosphatase rescue in cells and mice","pmids":["25939886"],"confidence":"High","gaps":["Identity of the relevant phosphatase and E3 ligase not defined","Upstream kinases for Ser935 not identified here"]},{"year":2015,"claim":"Showed LRRK2 autophosphorylates its ROC domain to accelerate GTP hydrolysis and drive dimerization, providing an intramolecular feedback link between its two enzymatic activities.","evidence":"In vitro kinase and GTP hydrolysis kinetics on purified ROC, size-exclusion dimerization, structural modeling, ROCO4 cross-phosphorylation","pmids":["26396237"],"confidence":"High","gaps":["In vivo relevance of ROC autophosphorylation not established","How dimerization relates to membrane activation unknown"]},{"year":2015,"claim":"Expanded the LRRK2 substrate repertoire beyond Rabs by identifying FAK and Tau as effectors with distinct dependence on kinase activity.","evidence":"Co-IP and in vitro kinase assays (FAK TXR/K phosphorylation; pY397 readouts) plus Tau fractionation and proteasomal degradation assays with kinase-dead mutant","pmids":["26365310","26014385"],"confidence":"Medium","gaps":["FAK and Tau effects characterized in separate contexts without unifying pathway","Tau interaction is single-lab Co-IP without structural detail"]},{"year":2017,"claim":"Provided structural definition of the multivalent 14-3-3:LRRK2 phosphopeptide interface and connected its disruption to kinase hyperactivation and toxicity.","evidence":"Crystal structures of 14-3-3 with LRRK2 phosphopeptides plus biochemical binding and cellular phenotype assays","pmids":["28202711"],"confidence":"High","gaps":["Structures use isolated phosphopeptides, not full-length LRRK2","Causal order between 14-3-3 loss and kinase activation not fully resolved"]},{"year":2018,"claim":"Demonstrated that wild-type LRRK2 kinase activity is pathologically elevated in human idiopathic PD dopamine neurons via oxidation, extending LRRK2 relevance beyond familial mutations.","evidence":"Proximity ligation assays for pSer1292-LRRK2 and 14-3-3 dissociation in human iPD tissue and rat models with Rab10 phosphorylation and organelle assays","pmids":["30045977"],"confidence":"High","gaps":["Precise oxidative trigger of activation not defined","Causal link between pRab10 and mitochondrial/lysosomal defects correlative"]},{"year":2018,"claim":"Connected LRRK2 kinase activity to α-synuclein propagation through Rab35, linking the kinase axis to a core PD pathology.","evidence":"Cell, C. elegans epistasis (constitutively active RAB35 rescue), and rodent synucleinopathy models with kinase inhibitor and Rab35 phosphorylation assays","pmids":["30150626"],"confidence":"High","gaps":["Molecular step from pRab35 to propagation not defined","Effector downstream of Rab35 in this context unidentified"]},{"year":2020,"claim":"Defined the LYTL pathway, establishing that LRRK2 acts at damaged lysosomes via phospho-Rab10/35-dependent JIP4 recruitment to drive membrane tubulation.","evidence":"Unbiased lysosomal proteomic screen, Co-IP, super-resolution and FIB-SEM imaging, kinase inhibition, Rab phosphorylation assays after LLOMe","pmids":["33177079"],"confidence":"High","gaps":["Cargo selectivity of LYTL tubules not defined","Physiological/in vivo consequences of LYTL unresolved"]},{"year":2020,"claim":"Placed LRRK2 in innate immune trafficking by showing phospho-Rab10 stalls macropinosome recycling to enable PI3K-Akt signaling in myeloid cells.","evidence":"Primary mouse/human macrophage, DC, and microglia cultures with kinase inhibition, Rab10 knockdown, EHBP1L1 overexpression, and chemotaxis/Akt readouts","pmids":["32853409"],"confidence":"High","gaps":["Relationship to neuronal LRRK2 functions unclear","In vivo immune consequences not established here"]},{"year":2020,"claim":"Showed endogenous Rab29 is dispensable for basal and stress-induced LRRK2 activity, correcting the model that Rab29 is the obligate physiological activator.","evidence":"Rab29 KO crossed into LRRK2/VPS35 knock-in mice with pRab10/pRab12 quantification and endolysosomal stress agents","pmids":["33135724"],"confidence":"High","gaps":["Identity of the genuine physiological activators left open at this stage","Possible context-specific Rab29 roles not excluded"]},{"year":2021,"claim":"Defined the molecular basis of LRRK2-driven ciliogenesis block, showing phospho-Rab10 recruits RILPL2/Myosin Va to the mother centriole.","evidence":"Co-IP, binding-domain mapping, FLIP microscopy of Myosin Va dynamics, and ciliogenesis assays in RPE cells with pathogenic LRRK2","pmids":["33727250"],"confidence":"High","gaps":["In vivo significance of ciliogenesis defect for PD unresolved","Tissue specificity of the effect unclear"]},{"year":2021,"claim":"Linked hyperactive LRRK2 to defective axonal autophagosome transport via SPAG9/JIP4-driven motor imbalance.","evidence":"Live-cell imaging of autophagosome transport in G2019S neurons with kinase inhibition and motor-recruitment assays","pmids":["34110246"],"confidence":"Medium","gaps":["Single-lab live-imaging model","Direct Rab-to-JIP4 step on autophagosomes not biochemically isolated"]},{"year":2021,"claim":"Identified NSF as a G2019S substrate whose phosphorylation drives toxic aggregation reversible by autophagy.","evidence":"In vitro kinase assay, human PD tissue immunohistochemistry, and autophagy-induction rescue in G2019S BAC mice with behavioral readouts","pmids":["33876242"],"confidence":"Medium","gaps":["NSF phosphosite-to-aggregation mechanism not fully defined","Single-lab finding"]},{"year":2021,"claim":"Used Type I vs Type II inhibitors to distinguish conformational from catalytic readouts, clarifying that Ser935 biomarker sites report kinase conformation rather than activity per se.","evidence":"Comparative inhibitor pharmacology with pRab10/pRab12 and pSer935 assays, mitophagy readouts, and A2016T resistance mutant","pmids":["34515301"],"confidence":"High","gaps":["Structural basis of conformation-coupled Ser935 phosphorylation not solved here","In vivo translation of mitophagy effect not established"]},{"year":2022,"claim":"Provided the cryo-EM basis for LRRK2-microtubule binding, mapping GTPase-domain residues that mediate the interaction independently of kinase activity.","evidence":"Cryo-EM of the LRRK2 catalytic half on microtubules with mutagenesis validation in vitro and in cells and LRRK1 negative control","pmids":["36510024"],"confidence":"High","gaps":["Functional consequence of microtubule binding for trafficking/signaling unresolved","Full-length filament architecture context-dependent"]},{"year":2022,"claim":"Showed that LRRK2 activation is spatially encoded—membrane recruitment to any endolysosomal compartment suffices, and lysosomal positioning selectively tunes Rab10 phosphorylation and LYTL.","evidence":"Rapamycin-induced organelle targeting, lysosome positioning manipulations (ARL8B/SKIP, RILP, JIP4 knockdown), PPM1H knockdown, and pRab10/pRab12 imaging in Rab29 KO cells","pmids":["35580815","36256825"],"confidence":"High","gaps":["Endogenous signals dictating membrane recruitment not fully enumerated here","Why Rab10 but not Rab12 is position-restricted mechanistically open"]},{"year":2023,"claim":"Identified Rab12 as a damaged-lysosome recruiter that locally amplifies LRRK2-dependent Rab10 phosphorylation, with PD variants increasing lysosomal LRRK2.","evidence":"Targeted siRNA screen, immunopurified lysosome assays, Rab12 recruitment and pRab10 quantification in LRRK2 R1441G and VPS35 D620N knock-in models","pmids":["37874617"],"confidence":"High","gaps":["How Rab12 mechanistically recruits LRRK2 not fully defined","Relationship between Rab12 pathway and CASM/STING pathway unresolved"]},{"year":2023,"claim":"Extended LRRK2 signaling to mitochondrial quality control in kidney, showing an MKK4/JNK-MFN2 degradation axis driving fragmentation.","evidence":"LRRK2 overexpression in human PTCs with MFN2 pSer27/ubiquitination assays and LRRK2 KO/inhibitor rescue in acute kidney injury mice","pmids":["37633049"],"confidence":"Medium","gaps":["Directness of LRRK2-to-MFN2 phosphorylation versus MKK4/JNK intermediary not fully separated","Relevance to neuronal LRRK2 biology unclear"]},{"year":2025,"claim":"Connected innate immune STING signaling to LRRK2 activation through the CASM pathway, identifying GABARAP-family ATG8 proteins as the selective recruiter.","evidence":"STING activation and CASM perturbation with lysosomal recruitment, kinase activity (pRab) readouts, and GABARAP vs LC3 dependency tests","pmids":["39812709"],"confidence":"High","gaps":["Structural basis of LRRK2-GABARAP recognition not defined","Integration with Rab12-dependent recruitment unresolved"]},{"year":null,"claim":"How the multiple converging activation inputs (Rab12, STING-CASM-GABARAP, lysosomal damage, oxidation) are integrated at the membrane to set LRRK2 kinase output, and how this maps to selective dopaminergic vulnerability in PD, remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model linking recruitment signals to graded kinase activation","Mechanism of cell-type-selective neurodegeneration not established","Full-length structural basis of membrane-bound active LRRK2 not solved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,5,7,8,9,14,20,22]},{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[0,5]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,5,8,9,22]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[9,17,18,19,21]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[1,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[12]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[16]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[18]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[10,18]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[1,9,10,17]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[13,14,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,21,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,7,8,14]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,10,21]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[4,6]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[12]}],"complexes":[],"partners":["RAB10","RAB12","RAB35","JIP4","14-3-3","PRKAR2B","RILPL2","MYO5A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q5S007","full_name":"Leucine-rich repeat serine/threonine-protein kinase 2","aliases":["Dardarin"],"length_aa":2527,"mass_kda":286.1,"function":"Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:21850687, PubMed:22012985, PubMed:23395371, PubMed:24687852, PubMed:25201882, PubMed:26014385, PubMed:26824392, PubMed:27830463, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421). Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation (PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421). Phosphorylates RAB3A, RAB3B, RAB3C, RAB3D, RAB5A, RAB5B, RAB5C, RAB8A, RAB8B, RAB10, RAB12, RAB29, RAB35, and RAB43 (PubMed:23395371, PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421, PubMed:38127736). Regulates the RAB3IP-catalyzed GDP/GTP exchange for RAB8A through the phosphorylation of 'Thr-72' on RAB8A (PubMed:26824392). Inhibits the interaction between RAB8A and GDI1 and/or GDI2 by phosphorylating 'Thr-72' on RAB8A (PubMed:26824392). Regulates primary ciliogenesis through phosphorylation of RAB8A and RAB10, which promotes SHH signaling in the brain (PubMed:29125462, PubMed:30398148). Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner (PubMed:23395371). Regulates neuronal process morphology in the intact central nervous system (CNS) (PubMed:17114044). Plays a role in synaptic vesicle trafficking (PubMed:24687852). Plays an important role in recruiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization (PubMed:25201882). Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway (PubMed:22012985). The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes (PubMed:22012985). Phosphorylates PRDX3 (PubMed:21850687). By phosphorylating APP on 'Thr-743', which promotes the production and the nuclear translocation of the APP intracellular domain (AICD), regulates dopaminergic neuron apoptosis (PubMed:28720718). Acts as a positive regulator of innate immunity by mediating phosphorylation of RIPK2 downstream of NOD1 and NOD2, thereby enhancing RIPK2 activation (PubMed:27830463). Independent of its kinase activity, inhibits the proteasomal degradation of MAPT, thus promoting MAPT oligomerization and secretion (PubMed:26014385). In addition, has GTPase activity via its Roc domain which regulates LRRK2 kinase activity (PubMed:18230735, PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29212815). Recruited by RAB29/RAB7L1 to overloaded lysosomes where it phosphorylates and stabilizes RAB8A and RAB10 which promote lysosomal content release and suppress lysosomal enlargement through the EHBP1 and EHBP1L1 effector proteins (PubMed:30209220, PubMed:38227290)","subcellular_location":"Cytoplasmic vesicle; Perikaryon; Golgi apparatus membrane; Cell projection, axon; Cell projection, dendrite; Endoplasmic reticulum membrane; Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane; Endosome; Lysosome; Mitochondrion outer membrane; Cytoplasm, cytoskeleton; Cytoplasmic vesicle, phagosome","url":"https://www.uniprot.org/uniprotkb/Q5S007/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LRRK2","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LRRK2","total_profiled":1310},"omim":[{"mim_id":"620923","title":"PARKINSON DISEASE 26, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK26","url":"https://www.omim.org/entry/620923"},{"mim_id":"619583","title":"EH DOMAIN-BINDING PROTEIN 1-LIKE 1; EHBP1L1","url":"https://www.omim.org/entry/619583"},{"mim_id":"613888","title":"RAS HOMOLOG GENE FAMILY, MEMBER T1; RHOT1","url":"https://www.omim.org/entry/613888"},{"mim_id":"613164","title":"PARKINSON DISEASE 16; PARK16","url":"https://www.omim.org/entry/613164"},{"mim_id":"613146","title":"MICRO RNA 184; MIR184","url":"https://www.omim.org/entry/613146"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Basal body","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nuclear membrane","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":49.4}],"url":"https://www.proteinatlas.org/search/LRRK2"},"hgnc":{"alias_symbol":["ROCO2","DKFZp434H2111","FLJ45829","RIPK7"],"prev_symbol":["PARK8"]},"alphafold":{"accession":"Q5S007","domains":[{"cath_id":"1.25.10,1.25.10","chopping":"249-327_350-428","consensus_level":"medium","plddt":86.1882,"start":249,"end":428},{"cath_id":"3.80.10.10","chopping":"1177-1328","consensus_level":"medium","plddt":84.17,"start":1177,"end":1328},{"cath_id":"1.10.510.10","chopping":"1951-2124","consensus_level":"high","plddt":80.3918,"start":1951,"end":2124},{"cath_id":"2.40.128.630","chopping":"2135-2150_2308-2401_2410-2527","consensus_level":"medium","plddt":80.9411,"start":2135,"end":2527},{"cath_id":"1.25.40","chopping":"477-515_532-595","consensus_level":"medium","plddt":81.9647,"start":477,"end":595}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5S007","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q5S007-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q5S007-F1-predicted_aligned_error_v6.png","plddt_mean":77.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LRRK2","jax_strain_url":"https://www.jax.org/strain/search?query=LRRK2"},"sequence":{"accession":"Q5S007","fasta_url":"https://rest.uniprot.org/uniprotkb/Q5S007.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q5S007/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5S007"}},"corpus_meta":[{"pmid":"30045977","id":"PMC_30045977","title":"LRRK2 activation in idiopathic Parkinson's disease.","date":"2018","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30045977","citation_count":392,"is_preprint":false},{"pmid":"31980808","id":"PMC_31980808","title":"LRRK2 in Parkinson disease: challenges of clinical trials.","date":"2020","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31980808","citation_count":367,"is_preprint":false},{"pmid":"16272164","id":"PMC_16272164","title":"Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.","date":"2005","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16272164","citation_count":254,"is_preprint":false},{"pmid":"15880653","id":"PMC_15880653","title":"An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.","date":"2005","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15880653","citation_count":218,"is_preprint":false},{"pmid":"33177079","id":"PMC_33177079","title":"LRRK2 mediates tubulation and vesicle sorting from lysosomes.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33177079","citation_count":204,"is_preprint":false},{"pmid":"17623048","id":"PMC_17623048","title":"Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17623048","citation_count":200,"is_preprint":false},{"pmid":"25391693","id":"PMC_25391693","title":"The role of the LRRK2 gene in Parkinsonism.","date":"2014","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/25391693","citation_count":181,"is_preprint":false},{"pmid":"30837320","id":"PMC_30837320","title":"LRRK2 links genetic and sporadic Parkinson's disease.","date":"2019","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/30837320","citation_count":169,"is_preprint":false},{"pmid":"24464040","id":"PMC_24464040","title":"LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.","date":"2014","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24464040","citation_count":169,"is_preprint":false},{"pmid":"26078453","id":"PMC_26078453","title":"Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26078453","citation_count":169,"is_preprint":false},{"pmid":"27927216","id":"PMC_27927216","title":"LRRK2 at the interface of autophagosomes, endosomes and lysosomes.","date":"2016","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/27927216","citation_count":144,"is_preprint":false},{"pmid":"17346966","id":"PMC_17346966","title":"LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins.","date":"2007","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/17346966","citation_count":139,"is_preprint":false},{"pmid":"29473513","id":"PMC_29473513","title":"The Role of LRRK2 in Neurodegeneration of Parkinson Disease.","date":"2018","source":"Current neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29473513","citation_count":136,"is_preprint":false},{"pmid":"25899482","id":"PMC_25899482","title":"Cellular processes associated with LRRK2 function and dysfunction.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25899482","citation_count":135,"is_preprint":false},{"pmid":"25251388","id":"PMC_25251388","title":"LRRK2 pathobiology in Parkinson's disease.","date":"2014","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25251388","citation_count":131,"is_preprint":false},{"pmid":"20457952","id":"PMC_20457952","title":"LRRK2 and Parkinson disease.","date":"2010","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20457952","citation_count":128,"is_preprint":false},{"pmid":"17498648","id":"PMC_17498648","title":"Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17498648","citation_count":126,"is_preprint":false},{"pmid":"28764903","id":"PMC_28764903","title":"Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.","date":"2017","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28764903","citation_count":125,"is_preprint":false},{"pmid":"31769472","id":"PMC_31769472","title":"LRRK2 regulation of immune-pathways and inflammatory disease.","date":"2019","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/31769472","citation_count":123,"is_preprint":false},{"pmid":"34991886","id":"PMC_34991886","title":"LRRK2 and idiopathic Parkinson's disease.","date":"2022","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34991886","citation_count":122,"is_preprint":false},{"pmid":"30150626","id":"PMC_30150626","title":"LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30150626","citation_count":122,"is_preprint":false},{"pmid":"18045479","id":"PMC_18045479","title":"Dynamic and redundant regulation of LRRK2 and LRRK1 expression.","date":"2007","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18045479","citation_count":121,"is_preprint":false},{"pmid":"32523507","id":"PMC_32523507","title":"\"LRRK2: Autophagy and Lysosomal Activity\".","date":"2020","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32523507","citation_count":114,"is_preprint":false},{"pmid":"23938341","id":"PMC_23938341","title":"LRRK2: cause, risk, and mechanism.","date":"2013","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/23938341","citation_count":113,"is_preprint":false},{"pmid":"23066449","id":"PMC_23066449","title":"Brain Penetrant LRRK2 Inhibitor.","date":"2012","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/23066449","citation_count":107,"is_preprint":false},{"pmid":"29894679","id":"PMC_29894679","title":"LRRK2 and mitochondria: Recent advances and current views.","date":"2018","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/29894679","citation_count":104,"is_preprint":false},{"pmid":"26008812","id":"PMC_26008812","title":"LRRK2 Pathways Leading to Neurodegeneration.","date":"2015","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/26008812","citation_count":104,"is_preprint":false},{"pmid":"28028237","id":"PMC_28028237","title":"Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28028237","citation_count":102,"is_preprint":false},{"pmid":"18804399","id":"PMC_18804399","title":"Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.","date":"2008","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/18804399","citation_count":93,"is_preprint":false},{"pmid":"26365310","id":"PMC_26365310","title":"LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26365310","citation_count":90,"is_preprint":false},{"pmid":"33044192","id":"PMC_33044192","title":"LRRK2 and the Endolysosomal System in Parkinson's Disease.","date":"2020","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/33044192","citation_count":87,"is_preprint":false},{"pmid":"33266247","id":"PMC_33266247","title":"Pathological Functions of LRRK2 in Parkinson's Disease.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33266247","citation_count":80,"is_preprint":false},{"pmid":"24907399","id":"PMC_24907399","title":"LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.","date":"2014","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24907399","citation_count":79,"is_preprint":false},{"pmid":"16406842","id":"PMC_16406842","title":"LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?","date":"2006","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16406842","citation_count":77,"is_preprint":false},{"pmid":"32853409","id":"PMC_32853409","title":"LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes.","date":"2020","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/32853409","citation_count":76,"is_preprint":false},{"pmid":"28353276","id":"PMC_28353276","title":"Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353276","citation_count":72,"is_preprint":false},{"pmid":"26177462","id":"PMC_26177462","title":"Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26177462","citation_count":70,"is_preprint":false},{"pmid":"25939886","id":"PMC_25939886","title":"LRRK2 dephosphorylation increases its ubiquitination.","date":"2015","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/25939886","citation_count":60,"is_preprint":false},{"pmid":"34196120","id":"PMC_34196120","title":"LRRK2 recruitment, activity, and function in organelles.","date":"2021","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/34196120","citation_count":59,"is_preprint":false},{"pmid":"22441981","id":"PMC_22441981","title":"Mechanisms of LRRK2-mediated neurodegeneration.","date":"2012","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/22441981","citation_count":57,"is_preprint":false},{"pmid":"32256311","id":"PMC_32256311","title":"The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System.","date":"2020","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32256311","citation_count":56,"is_preprint":false},{"pmid":"33769432","id":"PMC_33769432","title":"Parkinson's disease and mitophagy: an emerging role for LRRK2.","date":"2021","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/33769432","citation_count":56,"is_preprint":false},{"pmid":"19142648","id":"PMC_19142648","title":"LRRK2 and neurodegeneration.","date":"2009","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/19142648","citation_count":55,"is_preprint":false},{"pmid":"28202711","id":"PMC_28202711","title":"Structural interface between LRRK2 and 14-3-3 protein.","date":"2017","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/28202711","citation_count":55,"is_preprint":false},{"pmid":"33135724","id":"PMC_33135724","title":"Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity.","date":"2020","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/33135724","citation_count":53,"is_preprint":false},{"pmid":"17804834","id":"PMC_17804834","title":"LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.","date":"2007","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17804834","citation_count":52,"is_preprint":false},{"pmid":"32612495","id":"PMC_32612495","title":"LRRK2 Phosphorylation, More Than an Epiphenomenon.","date":"2020","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32612495","citation_count":51,"is_preprint":false},{"pmid":"28202669","id":"PMC_28202669","title":"The LRRK2-macroautophagy axis and its relevance to Parkinson's disease.","date":"2017","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/28202669","citation_count":51,"is_preprint":false},{"pmid":"28353279","id":"PMC_28353279","title":"Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353279","citation_count":50,"is_preprint":false},{"pmid":"34515301","id":"PMC_34515301","title":"Impact of Type II LRRK2 inhibitors on signaling and mitophagy.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34515301","citation_count":50,"is_preprint":false},{"pmid":"28353280","id":"PMC_28353280","title":"LRRK2 and Autophagy.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353280","citation_count":49,"is_preprint":false},{"pmid":"22988866","id":"PMC_22988866","title":"The GTPase function of LRRK2.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22988866","citation_count":48,"is_preprint":false},{"pmid":"19804416","id":"PMC_19804416","title":"LRRK2 in Parkinson's disease: biochemical functions.","date":"2009","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19804416","citation_count":48,"is_preprint":false},{"pmid":"28353282","id":"PMC_28353282","title":"LRRK2 and the Immune System.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353282","citation_count":47,"is_preprint":false},{"pmid":"26396237","id":"PMC_26396237","title":"LRRK2 autophosphorylation enhances its GTPase activity.","date":"2015","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/26396237","citation_count":46,"is_preprint":false},{"pmid":"24025585","id":"PMC_24025585","title":"Contribution of GTPase activity to LRRK2-associated Parkinson disease.","date":"2013","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/24025585","citation_count":45,"is_preprint":false},{"pmid":"36256825","id":"PMC_36256825","title":"Lysosomal positioning regulates Rab10 phosphorylation at LRRK2+ lysosomes.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36256825","citation_count":44,"is_preprint":false},{"pmid":"31920513","id":"PMC_31920513","title":"Autophagy and LRRK2 in the Aging Brain.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31920513","citation_count":44,"is_preprint":false},{"pmid":"30578345","id":"PMC_30578345","title":"The role of LRRK2 in cell signalling.","date":"2018","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/30578345","citation_count":42,"is_preprint":false},{"pmid":"18097165","id":"PMC_18097165","title":"Mutations in LRRK2 as a cause of Parkinson's disease.","date":"2007","source":"Neuro-Signals","url":"https://pubmed.ncbi.nlm.nih.gov/18097165","citation_count":42,"is_preprint":false},{"pmid":"16758483","id":"PMC_16758483","title":"Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease.","date":"2006","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/16758483","citation_count":42,"is_preprint":false},{"pmid":"33727250","id":"PMC_33727250","title":"LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ciliogenesis blockade.","date":"2021","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/33727250","citation_count":41,"is_preprint":false},{"pmid":"39812709","id":"PMC_39812709","title":"A STING-CASM-GABARAP pathway activates LRRK2 at lysosomes.","date":"2025","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/39812709","citation_count":40,"is_preprint":false},{"pmid":"30467121","id":"PMC_30467121","title":"LRRK2 and Rab GTPases.","date":"2018","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/30467121","citation_count":39,"is_preprint":false},{"pmid":"22988873","id":"PMC_22988873","title":"Phosphorylation of LRRK2: from kinase to substrate.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22988873","citation_count":39,"is_preprint":false},{"pmid":"26014385","id":"PMC_26014385","title":"LRRK2 Promotes Tau Accumulation, Aggregation and Release.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26014385","citation_count":39,"is_preprint":false},{"pmid":"27521182","id":"PMC_27521182","title":"LRRK2 variation and dementia with Lewy bodies.","date":"2016","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/27521182","citation_count":38,"is_preprint":false},{"pmid":"33197196","id":"PMC_33197196","title":"Selective Inhibitors of G2019S-LRRK2 Kinase Activity.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33197196","citation_count":37,"is_preprint":false},{"pmid":"33006315","id":"PMC_33006315","title":"Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33006315","citation_count":37,"is_preprint":false},{"pmid":"36510024","id":"PMC_36510024","title":"Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.","date":"2022","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/36510024","citation_count":36,"is_preprint":false},{"pmid":"30915830","id":"PMC_30915830","title":"LRRK2 in Infection: Friend or Foe?","date":"2019","source":"ACS infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/30915830","citation_count":35,"is_preprint":false},{"pmid":"31813996","id":"PMC_31813996","title":"G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31813996","citation_count":35,"is_preprint":false},{"pmid":"35580815","id":"PMC_35580815","title":"Directing LRRK2 to membranes of the endolysosomal pathway triggers RAB phosphorylation and JIP4 recruitment.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35580815","citation_count":35,"is_preprint":false},{"pmid":"28353287","id":"PMC_28353287","title":"Mechanisms of Mutant LRRK2 Neurodegeneration.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353287","citation_count":33,"is_preprint":false},{"pmid":"32247534","id":"PMC_32247534","title":"Leucine-rich repeat kinase-2 (LRRK2) modulates microglial phenotype and dopaminergic neurodegeneration.","date":"2020","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/32247534","citation_count":33,"is_preprint":false},{"pmid":"37874617","id":"PMC_37874617","title":"Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/37874617","citation_count":33,"is_preprint":false},{"pmid":"31138985","id":"PMC_31138985","title":"Rab GTPases as Physiological Substrates of LRRK2 Kinase.","date":"2019","source":"Experimental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31138985","citation_count":32,"is_preprint":false},{"pmid":"29308544","id":"PMC_29308544","title":"The LRRK2 signalling system.","date":"2018","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/29308544","citation_count":31,"is_preprint":false},{"pmid":"35427743","id":"PMC_35427743","title":"LRRK2 as a target for modulating immune system responses.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35427743","citation_count":31,"is_preprint":false},{"pmid":"30048714","id":"PMC_30048714","title":"The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.","date":"2018","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30048714","citation_count":31,"is_preprint":false},{"pmid":"28202680","id":"PMC_28202680","title":"Cross-talk between LRRK2 and PKA: implication for Parkinson's disease?","date":"2017","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/28202680","citation_count":30,"is_preprint":false},{"pmid":"25703537","id":"PMC_25703537","title":"Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond.","date":"2015","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/25703537","citation_count":30,"is_preprint":false},{"pmid":"25897865","id":"PMC_25897865","title":"Structural Characterization of LRRK2 Inhibitors.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25897865","citation_count":30,"is_preprint":false},{"pmid":"22166430","id":"PMC_22166430","title":"Mouse models for LRRK2 Parkinson's disease.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22166430","citation_count":29,"is_preprint":false},{"pmid":"28353288","id":"PMC_28353288","title":"Small-Molecule Inhibitors of LRRK2.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353288","citation_count":28,"is_preprint":false},{"pmid":"22988875","id":"PMC_22988875","title":"LRRK2 and vesicle trafficking.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22988875","citation_count":28,"is_preprint":false},{"pmid":"32982917","id":"PMC_32982917","title":"Mitochondrial Mechanisms of LRRK2 G2019S Penetrance.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32982917","citation_count":28,"is_preprint":false},{"pmid":"25888648","id":"PMC_25888648","title":"LRRK2 mutations and neurotoxicant susceptibility.","date":"2015","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/25888648","citation_count":27,"is_preprint":false},{"pmid":"34110246","id":"PMC_34110246","title":"Hyperactive LRRK2 kinase impairs the trafficking of axonal autophagosomes.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34110246","citation_count":26,"is_preprint":false},{"pmid":"33876242","id":"PMC_33876242","title":"LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation.","date":"2021","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33876242","citation_count":25,"is_preprint":false},{"pmid":"22988879","id":"PMC_22988879","title":"A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22988879","citation_count":25,"is_preprint":false},{"pmid":"20403420","id":"PMC_20403420","title":"Expression of leucine-rich-repeat-kinase 2 (LRRK2) during embryonic development.","date":"2010","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20403420","citation_count":24,"is_preprint":false},{"pmid":"37633049","id":"PMC_37633049","title":"LRRK2 aggravates kidney injury through promoting MFN2 degradation and abnormal mitochondrial integrity.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37633049","citation_count":23,"is_preprint":false},{"pmid":"30467120","id":"PMC_30467120","title":"The role of LRRK2 in cytoskeletal dynamics.","date":"2018","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/30467120","citation_count":23,"is_preprint":false},{"pmid":"25071441","id":"PMC_25071441","title":"Interaction of LRRK2 with kinase and GTPase signaling cascades.","date":"2014","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25071441","citation_count":23,"is_preprint":false},{"pmid":"34929286","id":"PMC_34929286","title":"LRRK2 correlates with macrophage infiltration in pan-cancer.","date":"2021","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34929286","citation_count":23,"is_preprint":false},{"pmid":"32714591","id":"PMC_32714591","title":"Physiological and pathological functions of LRRK2: implications from substrate proteins.","date":"2018","source":"Neuronal signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32714591","citation_count":23,"is_preprint":false},{"pmid":"21676337","id":"PMC_21676337","title":"Role of LRRK2 kinase dysfunction in Parkinson disease.","date":"2011","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21676337","citation_count":23,"is_preprint":false},{"pmid":"31174552","id":"PMC_31174552","title":"Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype.","date":"2019","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31174552","citation_count":23,"is_preprint":false},{"pmid":"28353278","id":"PMC_28353278","title":"LRRK2 Phosphorylation.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353278","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43335,"output_tokens":7810,"usd":0.123578,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16942,"output_tokens":7072,"usd":0.130755,"stage2_stop_reason":"end_turn"},"total_usd":0.254333,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"LRRK2 possesses both kinase and GTPase activity. Purified brain LRRK2 binds and hydrolyzes GTP. PD mutations R1441C/G in the GTPase (ROC) domain reduce GTP hydrolysis activity. GTPase activity of LRRK2 can function independently of kinase activity, whereas kinase activity requires the presence of the GTPase domain.\",\n      \"method\": \"In vitro GTP binding and hydrolysis assays using purified LRRK2 from transgenic mouse brain and transfected cell cultures; domain deletion constructs\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzymatic assay with purified protein, domain-deletion and mutant constructs, replicated across tissue and cell systems\",\n      \"pmids\": [\"17623048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"C. elegans LRK-1 (LRRK2 ortholog) localizes to the Golgi apparatus and is required for polarized sorting of synaptic vesicle (SV) proteins to axons. In lrk-1 deletion mutants, SV proteins mislocalize to dendrites. This mislocalization depends on the AP-1 µ1 adaptor UNC-101 (dendritic transport) but not on UNC-104 kinesin (axonal transport), placing LRK-1 upstream of the dendritic sorting machinery at the Golgi.\",\n      \"method\": \"C. elegans genetics; lrk-1 deletion mutants; in vivo imaging of fluorescently tagged SV proteins; epistasis with unc-101 and unc-104 mutants; immunolocalization of LRK-1 to Golgi\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic loss-of-function with defined cellular phenotype, epistasis analysis, and direct localization in a validated ortholog model\",\n      \"pmids\": [\"17346966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss of Drosophila LRRK (sole ortholog of human LRRK2) causes degeneration of dopaminergic neurons (reduced tyrosine hydroxylase staining, shrunken morphology) and severely impaired locomotor activity, establishing an in vivo requirement for LRRK2 in dopaminergic neuron integrity.\",\n      \"method\": \"Drosophila loss-of-function mutants (LRRK deletion); tyrosine hydroxylase immunostaining; locomotor behavioral assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with specific neuronal phenotype in an ortholog model, two orthogonal readouts (immunostaining + behavior), single lab\",\n      \"pmids\": [\"17498648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LRRK2 negatively regulates PKA activity in striatal projection neurons (SPNs) by interacting with PKA regulatory subunit IIβ (PKARIIβ). Loss of LRRK2 promotes synaptic translocation of PKA and increases PKA-mediated phosphorylation of cofilin and GluR1, causing abnormal synaptogenesis. The PD-linked R1441C mutation impairs LRRK2–PKARIIβ interaction, leading to excessive PKA activity.\",\n      \"method\": \"Co-immunoprecipitation; LRRK2 knockout mice; PKA activity assays; phosphorylation assays for cofilin and GluR1; synaptic fractionation; R1441C knock-in mice\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP identifying binding partner, KO and knock-in mice with defined cellular and biochemical phenotypes, multiple orthogonal methods\",\n      \"pmids\": [\"24464040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 kinase inhibition leads to dephosphorylation of Ser935 followed by ubiquitination (via K48 and K63 linkages) and degradation of LRRK2. PD mutations (R1441G, Y1699C, I2020T) and disruption of 14-3-3 binding (via difopein) also cause LRRK2 dephosphorylation and hyper-ubiquitination. Phosphatase activity is directly required for inhibitor/mutant-induced ubiquitination (calyculin A treatment prevents both dephosphorylation and increased ubiquitination).\",\n      \"method\": \"LRRK2 kinase inhibitor treatment (GNE1023); phosphorylation and stability assays in cells and mouse dosing studies; ubiquitination assays (K48/K63 linkage); PD mutant expression; difopein expression; phosphatase inhibitor calyculin A\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (pharmacological inhibition, genetic mutants, phosphatase inhibitor rescue) in cells and in vivo, single lab\",\n      \"pmids\": [\"25939886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 autophosphorylates its own ROC (GTPase) domain, and this phosphorylation enhances GTP hydrolysis rate (~2-fold). Phosphorylation also promotes ROC dimer formation and induces conformational changes at the p-loop. The ameba LRRK2 ortholog ROCO4 can phosphorylate human LRRK2 ROC on the same residues as human LRRK2 kinase.\",\n      \"method\": \"In vitro kinase assay with purified ROC domain; GTP hydrolysis kinetics (kcat measurement); GDP/GTP dissociation kinetics; size-exclusion chromatography for dimerization; structural modeling; phosphoproteomics alignment\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro enzymatic assay with kinetic measurements, structural modeling, cross-species validation with ROCO4, multiple readouts\",\n      \"pmids\": [\"26396237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"14-3-3 proteins bind LRRK2 at multiple phosphorylated serine residues in a multivalent interaction. Crystal structures of 14-3-3 with LRRK2 phosphopeptides characterize this structural interface. PD-relevant mutations impair 14-3-3 binding, which is linked to enhanced LRRK2 kinase activity, LRRK2 ubiquitination, inclusion body accumulation, and reduced neurite length.\",\n      \"method\": \"Biochemical binding assays; X-ray crystal structures of 14-3-3 with LRRK2 phosphopeptides\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus biochemical assays characterizing multivalent interaction, single lab but structural validation\",\n      \"pmids\": [\"28202711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Wild-type LRRK2 kinase activity is selectively enhanced in substantia nigra dopamine neurons in idiopathic PD (iPD) patients and rat models through an oxidative mechanism, resulting in phosphorylation of the LRRK2 substrate Rab10 and downstream abnormalities in mitochondrial protein import and lysosomal function.\",\n      \"method\": \"Proximity ligation assays (PLA) for pSer1292-LRRK2 and LRRK2/14-3-3 dissociation; postmortem human iPD brain tissue; rat PD models; Rab10 phosphorylation assays; mitochondrial import and lysosomal function assays\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — novel PLA methodology applied to human tissue and two independent animal models, multiple downstream functional readouts, single lab\",\n      \"pmids\": [\"30045977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LRRK2 modulates α-synuclein propagation in a kinase activity-dependent manner via phosphorylation of RAB35. The PD-linked G2019S mutation (increased kinase activity) enhances α-synuclein propagation efficiency. Constitutive RAB35 activation rescues the reduced α-synuclein propagation phenotype in lrk-1 C. elegans mutants (epistasis). LRRK2 kinase inhibition in mice reduces α-synuclein aggregation and enhances lysosomal degradation of α-synuclein.\",\n      \"method\": \"Cell culture, C. elegans, and rodent models; kinase inhibitor treatment; RAB35 phosphorylation assays; lrk-1 mutant epistasis with constitutively active RAB35; in vivo mouse synucleinopathy model with LRRK2 inhibitor\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistasis in C. elegans, multiple model systems (cell/worm/rodent), pharmacological and genetic perturbations converging on the same pathway\",\n      \"pmids\": [\"30150626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRRK2 is recruited to lysosomes after lysosomal membrane damage (LLOMe treatment) and phosphorylates RAB35 and RAB10, which recruits the motor adaptor protein JIP4 to the lysosomal membrane in a kinase-dependent manner. JIP4 then promotes the formation of LAMP1-negative membranous tubules that release vesicular content from lysosomes — a process named LYTL (LYsosomal Tubulation/sorting driven by LRRK2).\",\n      \"method\": \"Unbiased proteomic screen for LRRK2 partners at lysosomal membrane; Co-IP; super-resolution live-cell imaging; FIB-SEM; kinase inhibitor treatments; RAB phosphorylation assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — proteomic screen followed by Co-IP, multiple imaging modalities (super-resolution + FIB-SEM), kinase-dependence established, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33177079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRRK2 phosphorylates cytoplasmic PI(3,4,5)P3-positive GTP-Rab10 before EEA1/Rab5 recruitment to macropinosomes, and LRRK2-phosphorylated Rab10 blocks EHBP1L1-mediated recycling tubules from macropinosomes. This stalls fast vesicle recycling to promote PI3K-Akt immunological responses (CCR5-loaded signaling endosomes, Akt activation, chemotaxis) in macrophages, dendritic cells, and microglia.\",\n      \"method\": \"Mouse and human primary macrophage/DC/microglia cultures; LRRK2 kinase inhibitor treatment; Rab10 knockdown; EHBP1L1 overexpression; endocytosis assays (macropinocytosis, phagocytosis, clathrin-mediated); live-cell imaging; Akt and chemotaxis functional assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple primary cell types, genetic and pharmacological perturbations, multiple orthogonal functional readouts, mechanistic pathway placement\",\n      \"pmids\": [\"32853409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Endogenous Rab29 knockout does not influence basal LRRK2 activity (measured by Rab10 and Rab12 phosphorylation) in wild-type, LRRK2[R1441C], or VPS35[D620N] knock-in mouse tissues or primary cells. Stimulation of Rab10/Rab12 phosphorylation by endolysosomal stressors (nigericin, monensin, chloroquine, LLOMe) is suppressed by LRRK2 inhibitors but not blocked by Rab29 deficiency.\",\n      \"method\": \"Rab29 knockout mice; LRRK2/VPS35 knock-in mice; phospho-Rab10 and phospho-Rab12 quantification in brain extracts and primary cells; LRRK2 inhibitor treatment; endolysosomal stress agents\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO in multiple knock-in mouse models, multiple LRRK2 substrates measured, pharmacological controls, negative result is informative and well-controlled\",\n      \"pmids\": [\"33135724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LRRK2-phosphorylated Rab10 recruits both RILPL2 and Myosin Va to the peri-centriolar region via high-affinity binding to the Myosin Va globular tail domain. In the presence of pathogenic LRRK2, phosphoRab10 retains Myosin Va at pericentriolar membranes (demonstrated by FLIP microscopy) and RILPL2/MyoVa relocalization to the mother centriole blocks ciliogenesis.\",\n      \"method\": \"Co-immunoprecipitation; fluorescence loss in photobleaching (FLIP) microscopy; overexpression of pathogenic LRRK2; RILPL2 overexpression; ciliogenesis assay in RPE cells; binding domain mapping\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays, FLIP microscopy for dynamics, functional ciliogenesis readout, domain-level mechanistic detail\",\n      \"pmids\": [\"33727250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hyperactive LRRK2 (G2019S mutation) disrupts processive axonal autophagosome transport in neurons in a kinase-dependent manner by recruiting the motor adaptor SPAG9/JIP4 to autophagosomal membranes. Increased SPAG9/JIP4 induces abnormal kinesin-1 recruitment and activation, producing a tug-of-war between anterograde and retrograde motors. This transport disruption correlates with defective autophagosome maturation.\",\n      \"method\": \"Live-cell imaging of autophagosome transport in neurons; LRRK2 G2019S expression; kinase inhibitor treatment; SPAG9/JIP4 recruitment assays; motor protein activity assays; maturation assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live imaging with defined cellular phenotype and proposed mechanistic model, kinase-dependence established, single lab\",\n      \"pmids\": [\"34110246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LRRK2 G2019S kinase activity phosphorylates NSF (N-ethylmaleimide sensitive factor) and induces its accumulation in toxic aggregates. NSF aggregates were observed in basal ganglia of G2019S PD patients and in cellular/animal G2019S models. Autophagy induction clears NSF aggregation and rescues motor/cognitive impairment in aged hG2019S BAC mice.\",\n      \"method\": \"In vitro kinase assay demonstrating LRRK2 phosphorylates NSF; immunohistochemistry in human PD brain tissue; cell and BAC mouse models; autophagy induction rescue experiments; behavioral assays\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay plus human tissue validation plus animal model rescue, multiple methods, single lab\",\n      \"pmids\": [\"33876242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Type I LRRK2 inhibitors (GSK3357679A, MLi-2) and Type II inhibitors (GZD-824, Rebastinib, Ponatinib) both suppress phosphorylation of Rab10 and Rab12 and promote mitophagy. Type II inhibitors do not induce dephosphorylation of LRRK2 N-terminal biomarker sites (e.g., Ser935), indicating these biomarker sites report on the open vs. closed kinase conformation rather than purely on catalytic activity. The A2016T resistance mutation confers cross-resistance to both Type I and Type II inhibitors.\",\n      \"method\": \"Pharmacological comparison of Type I and II inhibitors; pRab10/pRab12 phosphorylation assays; pSer935 and related site assays; mitophagy assays; LRRK2[A2016T] resistance mutant\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple inhibitor classes, multiple substrates and phosphosites, resistance mutant validation, mechanistic interpretation of conformational states\",\n      \"pmids\": [\"34515301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structure of the LRRK2 catalytic half (kinase in closed conformation + GTPase domain) bound to microtubules identifies GTPase domain residues mediating microtubule binding. Mutagenesis of these residues disrupts microtubule binding in vitro and in cells without affecting kinase activity. LRRK1 (closely related) has a similar overall structure but does not interact with microtubules.\",\n      \"method\": \"Cryo-EM structure of LRRK2 catalytic half bound to microtubules; comparative structure of LRRK1; site-directed mutagenesis of GTPase residues; in vitro microtubule-binding assay; cell-based microtubule co-localization\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure with mutagenesis validation in vitro and in cells, negative control with LRRK1, mechanistic residue identification\",\n      \"pmids\": [\"36510024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRRK2 activation at lysosomes and the phosphorylation of Rab10 (but not Rab12) is restricted to perinuclear lysosomes by lysosomal positioning. Anterograde lysosome transport (via ARL8B/SKIP overexpression or JIP4 knockdown) blocks Rab10 recruitment and phosphorylation by LRRK2 and prevents LYTL tubulation. Conversely, perinuclear lysosomal clustering (via RILP overexpression) increases LRRK2-dependent Rab10 phosphorylation. Phosphatase PPM1H knockdown increases pRab10 signal and lysosomal tubulation in the perinuclear region.\",\n      \"method\": \"Rapamycin-dependent LRRK2 recruitment to lysosomes; ARL8B/SKIP overexpression; JIP4 knockdown; RILP overexpression; pRab10 and pRab12 quantification by immunofluorescence; PPM1H siRNA knockdown; live-cell imaging\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple gain- and loss-of-function perturbations, differential substrate regulation identified, phosphatase component identified, multiple orthogonal methods\",\n      \"pmids\": [\"36256825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Directing LRRK2 to any membrane of the endolysosomal pathway (Golgi, lysosomes, plasma membrane, recycling/early/late endosomes) via rapamycin-induced oligomerization is sufficient to trigger local phosphorylation of RAB10, RAB12, and recruitment of JIP4, independent of endogenous RAB29.\",\n      \"method\": \"Rapamycin-dependent organelle-targeting system; pRAB10 and pRAB12 immunofluorescence; JIP4 recruitment assay; RAB29 knockout cells\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic targeting to multiple organelles, negative control with Rab29 KO, multiple substrate readouts, mechanistic conclusion about membrane sufficiency for activation\",\n      \"pmids\": [\"35580815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Rab12 acts as a novel regulator of LRRK2 activity at lysosomes. Rab12 is recruited to damaged lysosomes and promotes a local, LRRK2-dependent increase in Rab10 phosphorylation at the lysosome. PD-linked variants LRRK2 R1441G and VPS35 D620N increase LRRK2 recruitment to lysosomes and elevate lysosomal pT73-Rab10 levels.\",\n      \"method\": \"Targeted siRNA screen; imaging and immunopurification of isolated lysosomes; Rab12 recruitment assays; pRab10 quantification at lysosomes; LRRK2 R1441G and VPS35 D620N knock-in models\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA screen identification plus lysosome-specific assays with immunopurification, multiple PD-linked variants tested, mechanistic pathway defined\",\n      \"pmids\": [\"37874617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LRRK2 promotes MFN2 degradation via LRRK2-MKK4/JNK-dependent phosphorylation of MFN2 at Ser27, followed by ubiquitination-mediated MFN2 degradation. This leads to mitochondrial fragmentation and increased ROS in proximal renal tubular cells. LRRK2 knockout prevents MFN2 loss and mitochondrial damage in acute kidney injury models.\",\n      \"method\": \"LRRK2 overexpression in human PTCs; MFN2 phosphorylation (pSer27) assays; ubiquitination assays; LRRK2 KO mice in AKI model; mitochondrial morphology analysis; ROS measurement; in vivo LRRK2 inhibitor pretreatment\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined phosphorylation site on substrate, KO rescue in vivo, pharmacological inhibitor validation, single lab\",\n      \"pmids\": [\"37633049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"STING signaling activates LRRK2 kinase activity and recruits it to lysosomes via the CASM (conjugation of ATG8 to single membranes) pathway. Multiple lysosome-perturbing stimuli (beyond STING) converge on CASM to activate LRRK2. LRRK2 lysosomal recruitment and kinase activation are highly dependent on interactions with the GABARAP subfamily of ATG8 proteins, not other ATG8 family members.\",\n      \"method\": \"STING activation assays; CASM pathway perturbation; lysosomal recruitment assays; LRRK2 kinase activity assays (pRab readout); selective GABARAP vs. LC3 dependency experiments\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple stimuli converging on common pathway, specific ATG8 family member identified, lysosomal recruitment and kinase activation linked, multiple orthogonal perturbations\",\n      \"pmids\": [\"39812709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 binds focal adhesion kinase (FAK) and phosphorylates FAK at its Thr-X-Arg/Lys (TXR/K) motif(s), reducing FAK autophosphorylation at Y397 and attenuating FAK activity. The G2019S-LRRK2 mutation decreases pY397-FAK levels in brain, microglia, and HEK cells, resulting in impaired microglial motility and delayed isolation of injury sites. LRRK2 kinase inhibitor restores pY397 and rescues microglial motility.\",\n      \"method\": \"Co-immunoprecipitation of LRRK2 and FAK; in vitro kinase assay (pTXR/K phosphorylation); pY397-FAK quantification in G2019S transgenic mice brain and microglia; microglial motility assays; LRRK2 kinase inhibitor rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP identifies interaction, kinase assay identifies phosphorylation site, in vivo and cell models with functional readout, pharmacological rescue\",\n      \"pmids\": [\"26365310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 interacts with Tau and promotes accumulation of non-monomeric and high-molecular weight Tau species independent of LRRK2 kinase activity. LRRK2 increases Tau secretion, possibly through impairment of Tau proteasomal degradation.\",\n      \"method\": \"Co-immunoprecipitation of LRRK2 and Tau; biochemical fractionation of Tau species (HMW); proteasomal degradation assays; kinase-dead LRRK2 mutant\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP showing interaction, biochemical assays for Tau species and secretion, kinase-dead mutant, single lab with multiple methods\",\n      \"pmids\": [\"26014385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRRK2 pathogenic mutations (R1441C, G2019S) reshape glutamatergic synapse structure and function in striatal SPNs: increased levels and altered nanoscale organization of AMPA receptors, decreased frequency of miniature EPSCs, and altered dendritic spine nano-architecture. Effects are pathway-specific (exaggerated in direct pathway dSPNs for R1441C).\",\n      \"method\": \"Biochemical synaptic preparations; super-resolution imaging; electrophysiology (mEPSC recording); two-photon glutamate uncaging; R1441C and G2019S knock-in mice; pathway-specific SPN identification\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (biochemistry, super-resolution, electrophysiology, two-photon uncaging) in knock-in mice, single lab\",\n      \"pmids\": [\"33006315\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LRRK2 is a large multidomain protein with both GTPase (ROC-COR) and serine/threonine kinase activities: its kinase phosphorylates a defined subset of Rab GTPases (including Rab8A/B, Rab10, Rab12, Rab29, Rab35) at a conserved switch-II motif, and this activity is enhanced by PD-linked mutations (especially G2019S in the kinase domain); GTP hydrolysis by the ROC domain is impaired by R1441C/G mutations and is itself regulated by LRRK2 autophosphorylation; LRRK2 is recruited to and activated at endolysosomal membranes through multiple converging signals (lysosomal damage, STING-CASM-GABARAP, Rab12), whereupon phospho-Rab10/35 recruit effectors such as JIP4 to drive lysosomal tubulation/sorting (LYTL), regulate macropinocytosis and immune signaling, and block ciliogenesis via Myosin Va/RILPL2 sequestration; in neurons LRRK2 negatively regulates PKA by binding PKARIIβ, affects axonal autophagosome transport via JIP4/kinesin-1 dysregulation, and phosphorylates NSF and FAK as additional substrates; phosphorylation of LRRK2 itself at Ser910/935/955/973 by upstream kinases promotes 14-3-3 binding and protein stability, while dephosphorylation of these sites—as seen with PD mutations or kinase inhibitors—leads to K48/K63 ubiquitination and degradation of LRRK2.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LRRK2 is a large dual-enzyme protein integrating GTPase (ROC-COR) and serine/threonine kinase activities, in which kinase function requires the GTPase domain and PD-linked ROC mutations (R1441C/G) impair GTP hydrolysis [#0]; LRRK2 also autophosphorylates its own ROC domain to enhance GTP hydrolysis and promote ROC dimerization, coupling its two catalytic modules [#5]. Its principal signaling output is phosphorylation of a defined set of Rab GTPases—Rab10, Rab12, and Rab35—an activity selectively elevated in idiopathic PD substantia nigra dopamine neurons through an oxidative mechanism with downstream mitochondrial and lysosomal consequences [#7], and enhanced by the gain-of-function G2019S kinase mutation [#8]. LRRK2 is recruited to and activated on endolysosomal membranes: membrane targeting to essentially any endolysosomal compartment is sufficient to trigger local Rab10/Rab12 phosphorylation and JIP4 recruitment [#18], with damaged-lysosome recruitment driven by Rab12 [#19] and by STING-CASM signaling acting selectively through GABARAP-family ATG8 proteins [#21]. Phospho-Rab effectors execute distinct cellular programs: phospho-Rab10/35 recruit the motor adaptor JIP4 to drive LYsosomal Tubulation/sorting (LYTL) [#9], and phospho-Rab10 recruits RILPL2/Myosin Va to the pericentriolar region to block ciliogenesis [#12]. LRRK2 kinase activity also disrupts processive axonal autophagosome transport via SPAG9/JIP4-driven aberrant kinesin-1 recruitment [#13], regulates macropinosome recycling and PI3K-Akt immune responses in myeloid cells through phospho-Rab10 [#10], and modulates α-synuclein propagation via Rab35 [#8]. Beyond Rab substrates, LRRK2 phosphorylates FAK to attenuate microglial motility [#22] and NSF to promote toxic aggregation [#14], and negatively regulates PKA signaling in striatal projection neurons by binding PKARIIβ [#3]. LRRK2 stability is governed by phosphorylation of N-terminal sites (e.g. Ser910/935) that recruit 14-3-3 through a multivalent interface [#6]; dephosphorylation—triggered by PD mutations, kinase inhibitors, or 14-3-3 disruption—leads to K48/K63 ubiquitination and degradation [#4]. Structurally, the closed-kinase catalytic half binds microtubules through defined GTPase-domain residues independently of kinase activity [#16]. In model organisms LRRK2 orthologs are required for dopaminergic neuron integrity [#2] and Golgi-based polarized sorting of synaptic vesicle proteins [#1].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Established that LRRK2 is a bifunctional enzyme whose kinase activity depends on its GTPase domain and whose GTP hydrolysis is reduced by PD-linked ROC mutations, defining the molecular architecture for all later signaling work.\",\n      \"evidence\": \"In vitro GTP binding/hydrolysis assays on purified brain and cell-derived LRRK2 with domain-deletion and R1441C/G constructs\",\n      \"pmids\": [\"17623048\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify physiological kinase substrates\", \"Mechanism coupling GTPase state to kinase output not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Ortholog genetics linked LRRK2 to neuronal membrane trafficking and dopaminergic neuron survival, providing the first in vivo functional context.\",\n      \"evidence\": \"C. elegans lrk-1 deletion with SV-protein sorting/epistasis and Drosophila LRRK loss-of-function with TH staining and locomotor assays\",\n      \"pmids\": [\"17346966\", \"17498648\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular substrates underlying sorting/survival defects unknown\", \"Connection between Golgi sorting role and kinase activity not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a kinase-independent role through which LRRK2 restrains PKA signaling at striatal synapses, showing LRRK2 acts via protein-protein interaction as well as catalysis.\",\n      \"evidence\": \"Reciprocal Co-IP with PKARIIβ, LRRK2 KO and R1441C knock-in mice, PKA activity and cofilin/GluR1 phosphorylation assays\",\n      \"pmids\": [\"24464040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How R1441C specifically weakens PKARIIβ binding not structurally defined\", \"Relationship to kinase-substrate pathway unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved how LRRK2 stability is regulated, linking N-terminal phosphorylation and 14-3-3 binding to ubiquitin-dependent degradation, explaining why PD mutations and inhibitors destabilize LRRK2.\",\n      \"evidence\": \"Kinase inhibitor (GNE1023) and PD-mutant studies with K48/K63 ubiquitination assays and calyculin A phosphatase rescue in cells and mice\",\n      \"pmids\": [\"25939886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the relevant phosphatase and E3 ligase not defined\", \"Upstream kinases for Ser935 not identified here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed LRRK2 autophosphorylates its ROC domain to accelerate GTP hydrolysis and drive dimerization, providing an intramolecular feedback link between its two enzymatic activities.\",\n      \"evidence\": \"In vitro kinase and GTP hydrolysis kinetics on purified ROC, size-exclusion dimerization, structural modeling, ROCO4 cross-phosphorylation\",\n      \"pmids\": [\"26396237\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of ROC autophosphorylation not established\", \"How dimerization relates to membrane activation unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Expanded the LRRK2 substrate repertoire beyond Rabs by identifying FAK and Tau as effectors with distinct dependence on kinase activity.\",\n      \"evidence\": \"Co-IP and in vitro kinase assays (FAK TXR/K phosphorylation; pY397 readouts) plus Tau fractionation and proteasomal degradation assays with kinase-dead mutant\",\n      \"pmids\": [\"26365310\", \"26014385\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FAK and Tau effects characterized in separate contexts without unifying pathway\", \"Tau interaction is single-lab Co-IP without structural detail\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided structural definition of the multivalent 14-3-3:LRRK2 phosphopeptide interface and connected its disruption to kinase hyperactivation and toxicity.\",\n      \"evidence\": \"Crystal structures of 14-3-3 with LRRK2 phosphopeptides plus biochemical binding and cellular phenotype assays\",\n      \"pmids\": [\"28202711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures use isolated phosphopeptides, not full-length LRRK2\", \"Causal order between 14-3-3 loss and kinase activation not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated that wild-type LRRK2 kinase activity is pathologically elevated in human idiopathic PD dopamine neurons via oxidation, extending LRRK2 relevance beyond familial mutations.\",\n      \"evidence\": \"Proximity ligation assays for pSer1292-LRRK2 and 14-3-3 dissociation in human iPD tissue and rat models with Rab10 phosphorylation and organelle assays\",\n      \"pmids\": [\"30045977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise oxidative trigger of activation not defined\", \"Causal link between pRab10 and mitochondrial/lysosomal defects correlative\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected LRRK2 kinase activity to α-synuclein propagation through Rab35, linking the kinase axis to a core PD pathology.\",\n      \"evidence\": \"Cell, C. elegans epistasis (constitutively active RAB35 rescue), and rodent synucleinopathy models with kinase inhibitor and Rab35 phosphorylation assays\",\n      \"pmids\": [\"30150626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular step from pRab35 to propagation not defined\", \"Effector downstream of Rab35 in this context unidentified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the LYTL pathway, establishing that LRRK2 acts at damaged lysosomes via phospho-Rab10/35-dependent JIP4 recruitment to drive membrane tubulation.\",\n      \"evidence\": \"Unbiased lysosomal proteomic screen, Co-IP, super-resolution and FIB-SEM imaging, kinase inhibition, Rab phosphorylation assays after LLOMe\",\n      \"pmids\": [\"33177079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cargo selectivity of LYTL tubules not defined\", \"Physiological/in vivo consequences of LYTL unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed LRRK2 in innate immune trafficking by showing phospho-Rab10 stalls macropinosome recycling to enable PI3K-Akt signaling in myeloid cells.\",\n      \"evidence\": \"Primary mouse/human macrophage, DC, and microglia cultures with kinase inhibition, Rab10 knockdown, EHBP1L1 overexpression, and chemotaxis/Akt readouts\",\n      \"pmids\": [\"32853409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship to neuronal LRRK2 functions unclear\", \"In vivo immune consequences not established here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed endogenous Rab29 is dispensable for basal and stress-induced LRRK2 activity, correcting the model that Rab29 is the obligate physiological activator.\",\n      \"evidence\": \"Rab29 KO crossed into LRRK2/VPS35 knock-in mice with pRab10/pRab12 quantification and endolysosomal stress agents\",\n      \"pmids\": [\"33135724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the genuine physiological activators left open at this stage\", \"Possible context-specific Rab29 roles not excluded\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the molecular basis of LRRK2-driven ciliogenesis block, showing phospho-Rab10 recruits RILPL2/Myosin Va to the mother centriole.\",\n      \"evidence\": \"Co-IP, binding-domain mapping, FLIP microscopy of Myosin Va dynamics, and ciliogenesis assays in RPE cells with pathogenic LRRK2\",\n      \"pmids\": [\"33727250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of ciliogenesis defect for PD unresolved\", \"Tissue specificity of the effect unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked hyperactive LRRK2 to defective axonal autophagosome transport via SPAG9/JIP4-driven motor imbalance.\",\n      \"evidence\": \"Live-cell imaging of autophagosome transport in G2019S neurons with kinase inhibition and motor-recruitment assays\",\n      \"pmids\": [\"34110246\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab live-imaging model\", \"Direct Rab-to-JIP4 step on autophagosomes not biochemically isolated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified NSF as a G2019S substrate whose phosphorylation drives toxic aggregation reversible by autophagy.\",\n      \"evidence\": \"In vitro kinase assay, human PD tissue immunohistochemistry, and autophagy-induction rescue in G2019S BAC mice with behavioral readouts\",\n      \"pmids\": [\"33876242\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NSF phosphosite-to-aggregation mechanism not fully defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Used Type I vs Type II inhibitors to distinguish conformational from catalytic readouts, clarifying that Ser935 biomarker sites report kinase conformation rather than activity per se.\",\n      \"evidence\": \"Comparative inhibitor pharmacology with pRab10/pRab12 and pSer935 assays, mitophagy readouts, and A2016T resistance mutant\",\n      \"pmids\": [\"34515301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of conformation-coupled Ser935 phosphorylation not solved here\", \"In vivo translation of mitophagy effect not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the cryo-EM basis for LRRK2-microtubule binding, mapping GTPase-domain residues that mediate the interaction independently of kinase activity.\",\n      \"evidence\": \"Cryo-EM of the LRRK2 catalytic half on microtubules with mutagenesis validation in vitro and in cells and LRRK1 negative control\",\n      \"pmids\": [\"36510024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of microtubule binding for trafficking/signaling unresolved\", \"Full-length filament architecture context-dependent\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed that LRRK2 activation is spatially encoded—membrane recruitment to any endolysosomal compartment suffices, and lysosomal positioning selectively tunes Rab10 phosphorylation and LYTL.\",\n      \"evidence\": \"Rapamycin-induced organelle targeting, lysosome positioning manipulations (ARL8B/SKIP, RILP, JIP4 knockdown), PPM1H knockdown, and pRab10/pRab12 imaging in Rab29 KO cells\",\n      \"pmids\": [\"35580815\", \"36256825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous signals dictating membrane recruitment not fully enumerated here\", \"Why Rab10 but not Rab12 is position-restricted mechanistically open\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified Rab12 as a damaged-lysosome recruiter that locally amplifies LRRK2-dependent Rab10 phosphorylation, with PD variants increasing lysosomal LRRK2.\",\n      \"evidence\": \"Targeted siRNA screen, immunopurified lysosome assays, Rab12 recruitment and pRab10 quantification in LRRK2 R1441G and VPS35 D620N knock-in models\",\n      \"pmids\": [\"37874617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Rab12 mechanistically recruits LRRK2 not fully defined\", \"Relationship between Rab12 pathway and CASM/STING pathway unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended LRRK2 signaling to mitochondrial quality control in kidney, showing an MKK4/JNK-MFN2 degradation axis driving fragmentation.\",\n      \"evidence\": \"LRRK2 overexpression in human PTCs with MFN2 pSer27/ubiquitination assays and LRRK2 KO/inhibitor rescue in acute kidney injury mice\",\n      \"pmids\": [\"37633049\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Directness of LRRK2-to-MFN2 phosphorylation versus MKK4/JNK intermediary not fully separated\", \"Relevance to neuronal LRRK2 biology unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected innate immune STING signaling to LRRK2 activation through the CASM pathway, identifying GABARAP-family ATG8 proteins as the selective recruiter.\",\n      \"evidence\": \"STING activation and CASM perturbation with lysosomal recruitment, kinase activity (pRab) readouts, and GABARAP vs LC3 dependency tests\",\n      \"pmids\": [\"39812709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LRRK2-GABARAP recognition not defined\", \"Integration with Rab12-dependent recruitment unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple converging activation inputs (Rab12, STING-CASM-GABARAP, lysosomal damage, oxidation) are integrated at the membrane to set LRRK2 kinase output, and how this maps to selective dopaminergic vulnerability in PD, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model linking recruitment signals to graded kinase activation\", \"Mechanism of cell-type-selective neurodegeneration not established\", \"Full-length structural basis of membrane-bound active LRRK2 not solved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 5, 7, 8, 9, 14, 20, 22]},\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 5, 8, 9, 22]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [9, 17, 18, 19, 21]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [1, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [10, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [1, 9, 10, 17]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13, 14, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 21, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 7, 8, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 10, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [4, 6]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RAB10\", \"RAB12\", \"RAB35\", \"JIP4\", \"14-3-3\", \"PRKAR2B\", \"RILPL2\", \"MYO5A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}